Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Enovis CorporationNYSE: ENOV
Cost of Revenue · Q1 FY2026 · quarter ended Apr 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $265.57M rose 17.2% year over year, ahead of the +5.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 17.3% from the prior quarter. Over 3 fiscal years it compounded at +9.2% a year.
Context
- Cost of revenue amounted to 40.2% of revenue in FY2025, down 3.8 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +17.2% holds above the trailing-twelve-month pace of +5.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 902.79M USD
- Year-over-year change
- -2.6%
- 4-year CAGR
- +8.6%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 902.79M | -2.6% |
| FY2024 | 2024-12-31 | 926.87M | +29.4% |
| FY2023 | 2023-12-31 | 716.42M | +3.3% |
| FY2022 | 2022-12-31 | 693.72M | +7.0% |
| FY2021 | 2021-12-31 | 648.51M | — |
Cost of Revenue vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's LTM Apr 2026 cost of revenue of $983.94M is the 7th highest of the 16 companies compared; the peer median is $640.09M.
- Its year-over-year change of +5.2% is the 11th highest of 16, against a peer median of +8.1%.
- Cost of revenue amounts to 43.2% of revenue for ENOV, versus a peer median of 64.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $3.1B | +28.7% | +7.2% | 65.4% | |
| LTM Jul 2026 | $2.54B | +5.6% | +3.8% | 65.4% | |
| LTM Jul 2026 | $2.21B | -7.2% | -9.0% | 62.0% | |
| LTM Jun 2026 | $1.98B | +4.9% | +6.5% | 55.3% | |
| LTM Sep 2026 | $1.46B | +7.4% | +0.6% | 64.6% | |
| LTM Jun 2026 | $1.37B | +16.3% | +3.7% | 51.2% | |
| LTM Apr 2026 | $983.94M | +5.2% | +9.2% | 43.2% | |
| LTM Jun 2026 | $700.3M | +13.3% | -1.0% | 57.2% | |
| LTM Jul 2026 | $640.09M | +13.6% | +3.8% | 55.6% | |
| LTM Jul 2026 | $600M | +11.1% | -1.1% | 67.3% | |
| LTM Jun 2026 | $487.49M | +4.7% | +7.6% | 69.4% | |
| LTM Feb 2026 | $321.47M | +8.1% | +0.5% | 51.4% | |
| LTM Mar 2026 | $281.8M | -9.3% | -3.5% | 75.9% | |
| LTM Mar 2026 | $187.54M | +19.4% | +12.5% | 76.5% | |
| LTM Apr 2026 | $146.01M | -1.0% | -7.9% | 80.3% | |
| LTM Mar 2026 | $43.8M | +13.6% | -3.0% | 44.7% | |
| Peer median (excluding ENOV) | $640.09M | +8.1% | +0.6% | 64.6% | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Cost of Revenue | 648.51M | 693.72M | 716.42M | 926.87M | 902.79M |
| Gross Profit | 777.68M | 869.38M | 990.78M | 1.18B | 1.35B |
| Gross Margin | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Research & Development | 49.09M | 60.83M | 75.33M | 91.3M | 120.33M |
| Selling, General & Admin | 665.78M | 772.91M | 830.31M | 939.36M | 1.07B |
| Operating Expenses | 840.47M | 940.56M | 1.06B | 1.96B | 1.36B |
| Depreciation & Amortization | 262.92M | 219.71M | 217.11M | 284.8M | 294.38M |
| EBITDA | 170.25M | 241.69M | 169.73M | (481.03M) | (830.22M) |
| EBITDA Margin | 11.9% | 15.5% | 9.9% | -22.8% | -36.9% |
| Operating Income | (62.8M) | (71.18M) | (65.71M) | (775.72M) | (18.87M) |
| Operating Margin | -4.4% | -4.6% | -3.8% | -36.8% | -0.8% |
| Interest Income | 0 | 200K | 0 | 0 | 0 |
| Interest Expense | 29.11M | 24.95M | 19.75M | 57.1M | 34.82M |
| Other Income / Expenses | (58.98M) | 69.11M | (1.42M) | (47.21M) | (1.14B) |
| Income Before Tax | (121.78M) | (2.07M) | (67.13M) | (822.92M) | (1.16B) |
| Pre-Tax Margin | -8.5% | -0.1% | -3.9% | -39.0% | -51.6% |
| Income Tax Expense | (19.53M) | 36.12M | (13.29M) | 4.49M | 22.29M |
| Net Income | 71.66M | (13.29M) | (33.26M) | (825.49M) | (1.18B) |
| Net Margin | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| EPS (Basic) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| EPS (Diluted) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| Weighted Avg Shares | 51.14M | 54.07M | 54.53M | 55.28M | 56.79M |
| Weighted Avg Shares (Diluted) | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.